Introduction to the special issue "Pharmacotherapies for the Treatment of Alcohol Abuse and Dependence" and a summary of patents targeting other neurotransmitter systems

Richard Bell, Kelle M. Franklin, Sheketha R. Hauser, Feng Zhou

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This paper introduces the Special Section: Pharmacotherapies for the Treatment of Alcohol Abuse and Dependence and provides a summary of patents targeting neurotransmitter systems not covered in the other four chapters. The World Health Organization notes that alcoholic-type drinking results in 2.5 million deaths per year, and these deaths occur to a disproportionately greater extent among adolescents and young adults. Developing a pharmacological treatment targeting alcohol abuse and dependence is complicated by (a) the heterogeneous nature of the disease(s), (b) alcohol affecting multiple neurotransmitter and neuromodulator systems, and (c) alcohol affecting multiple organ systems which in turn influence the function of the central nervous system. Presently, the USA Federal Drug Administration has approved three pharmacotherapies for alcoholism: disulfiram, naltrexone, and acamprosate. This chapter provides a summary of the following systems, which are not covered in the accompanying chapters; alcohol and acetaldehyde metabolism, opioid, glycinergic, GABA-A, neurosteroid, dopaminergic, serotonergic, and endocannabinoid, as well as patents targeting these systems for the treatment of alcoholism. Finally, an overview is presented on the use of pharmacogenetics and pharmacogenomics in tailoring treatments for certain subpopulations of alcoholics, which is expected to continue in the future.

Original languageEnglish
Pages (from-to)93-112
Number of pages20
JournalRecent Patents on CNS Drug Discovery
Volume7
Issue number2
StatePublished - Aug 2012

Fingerprint

Patents
Alcoholism
Neurotransmitter Agents
Drug Therapy
Pharmacogenetics
Alcohols
Therapeutics
Disulfiram
Endocannabinoids
Naltrexone
Acetaldehyde
Alcoholics
gamma-Aminobutyric Acid
Opioid Analgesics
Drinking
Young Adult
Central Nervous System
Pharmacology
Pharmaceutical Preparations

Keywords

  • Addiction
  • Agonist
  • Alcohol-use disorders
  • Allosteric modulator
  • Antagonist
  • Hormone
  • Metabolism
  • Neuromodulator

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Drug Discovery

Cite this

@article{8440bd7ea5924f05bd6f3f0fce9eb569,
title = "Introduction to the special issue {"}Pharmacotherapies for the Treatment of Alcohol Abuse and Dependence{"} and a summary of patents targeting other neurotransmitter systems",
abstract = "This paper introduces the Special Section: Pharmacotherapies for the Treatment of Alcohol Abuse and Dependence and provides a summary of patents targeting neurotransmitter systems not covered in the other four chapters. The World Health Organization notes that alcoholic-type drinking results in 2.5 million deaths per year, and these deaths occur to a disproportionately greater extent among adolescents and young adults. Developing a pharmacological treatment targeting alcohol abuse and dependence is complicated by (a) the heterogeneous nature of the disease(s), (b) alcohol affecting multiple neurotransmitter and neuromodulator systems, and (c) alcohol affecting multiple organ systems which in turn influence the function of the central nervous system. Presently, the USA Federal Drug Administration has approved three pharmacotherapies for alcoholism: disulfiram, naltrexone, and acamprosate. This chapter provides a summary of the following systems, which are not covered in the accompanying chapters; alcohol and acetaldehyde metabolism, opioid, glycinergic, GABA-A, neurosteroid, dopaminergic, serotonergic, and endocannabinoid, as well as patents targeting these systems for the treatment of alcoholism. Finally, an overview is presented on the use of pharmacogenetics and pharmacogenomics in tailoring treatments for certain subpopulations of alcoholics, which is expected to continue in the future.",
keywords = "Addiction, Agonist, Alcohol-use disorders, Allosteric modulator, Antagonist, Hormone, Metabolism, Neuromodulator",
author = "Richard Bell and Franklin, {Kelle M.} and Hauser, {Sheketha R.} and Feng Zhou",
year = "2012",
month = "8",
language = "English",
volume = "7",
pages = "93--112",
journal = "Recent Patents on CNS Drug Discovery",
issn = "1574-8898",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Introduction to the special issue "Pharmacotherapies for the Treatment of Alcohol Abuse and Dependence" and a summary of patents targeting other neurotransmitter systems

AU - Bell, Richard

AU - Franklin, Kelle M.

AU - Hauser, Sheketha R.

AU - Zhou, Feng

PY - 2012/8

Y1 - 2012/8

N2 - This paper introduces the Special Section: Pharmacotherapies for the Treatment of Alcohol Abuse and Dependence and provides a summary of patents targeting neurotransmitter systems not covered in the other four chapters. The World Health Organization notes that alcoholic-type drinking results in 2.5 million deaths per year, and these deaths occur to a disproportionately greater extent among adolescents and young adults. Developing a pharmacological treatment targeting alcohol abuse and dependence is complicated by (a) the heterogeneous nature of the disease(s), (b) alcohol affecting multiple neurotransmitter and neuromodulator systems, and (c) alcohol affecting multiple organ systems which in turn influence the function of the central nervous system. Presently, the USA Federal Drug Administration has approved three pharmacotherapies for alcoholism: disulfiram, naltrexone, and acamprosate. This chapter provides a summary of the following systems, which are not covered in the accompanying chapters; alcohol and acetaldehyde metabolism, opioid, glycinergic, GABA-A, neurosteroid, dopaminergic, serotonergic, and endocannabinoid, as well as patents targeting these systems for the treatment of alcoholism. Finally, an overview is presented on the use of pharmacogenetics and pharmacogenomics in tailoring treatments for certain subpopulations of alcoholics, which is expected to continue in the future.

AB - This paper introduces the Special Section: Pharmacotherapies for the Treatment of Alcohol Abuse and Dependence and provides a summary of patents targeting neurotransmitter systems not covered in the other four chapters. The World Health Organization notes that alcoholic-type drinking results in 2.5 million deaths per year, and these deaths occur to a disproportionately greater extent among adolescents and young adults. Developing a pharmacological treatment targeting alcohol abuse and dependence is complicated by (a) the heterogeneous nature of the disease(s), (b) alcohol affecting multiple neurotransmitter and neuromodulator systems, and (c) alcohol affecting multiple organ systems which in turn influence the function of the central nervous system. Presently, the USA Federal Drug Administration has approved three pharmacotherapies for alcoholism: disulfiram, naltrexone, and acamprosate. This chapter provides a summary of the following systems, which are not covered in the accompanying chapters; alcohol and acetaldehyde metabolism, opioid, glycinergic, GABA-A, neurosteroid, dopaminergic, serotonergic, and endocannabinoid, as well as patents targeting these systems for the treatment of alcoholism. Finally, an overview is presented on the use of pharmacogenetics and pharmacogenomics in tailoring treatments for certain subpopulations of alcoholics, which is expected to continue in the future.

KW - Addiction

KW - Agonist

KW - Alcohol-use disorders

KW - Allosteric modulator

KW - Antagonist

KW - Hormone

KW - Metabolism

KW - Neuromodulator

UR - http://www.scopus.com/inward/record.url?scp=84861724412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861724412&partnerID=8YFLogxK

M3 - Article

C2 - 22574678

AN - SCOPUS:84861724412

VL - 7

SP - 93

EP - 112

JO - Recent Patents on CNS Drug Discovery

JF - Recent Patents on CNS Drug Discovery

SN - 1574-8898

IS - 2

ER -